A. Gelibter

发表

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy

A. Marchetti, F. Buttitta, P. Visca, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Aromatase inhibitors in post-menopausal metastatic breast carcinoma

M. Pino, M. Milella, F. Cognetti, 2007, Expert opinion on investigational drugs.

New approaches to prevent intestinal toxicity of irinotecan-based regimens.

A. Vecchione, A. Alimonti, F. Cognetti, 2004, Cancer treatment reviews.

Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features

D. Galetta, S. Novello, F. de Marinis, 2021, Cancers.

Second- and third-generation aromatase inhibitors as first-line endocrine therapy in postmenopausal metastatic breast cancer patients: a pooled analysis of the randomised trials

S. Cosimo, S. Di Cosimo, M. Milella, 2006, British Journal of Cancer.

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real‐world evidence

N. Tinari, G. Ciliberto, G. Sanguineti, 2020 .

Bevacizumab: one treatment for all the seasons?

F. Cognetti, A. Gelibter, M. Zeuli, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer

F. di Costanzo, A. Gabriele, F. Cognetti, 2007, Current medical research and opinion.

Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained?

I. Sperduti, T. Gamucci, R. Grande, 2013, SpringerPlus.

Use of Adjuvant Chemotherapy After Surgery in Patients With Colon Cancer.

A. Gelibter, C. Mosillo, Grazia Sirgiovanni, 2017, JAMA surgery.

Renal Function Outcomes in Metastatic Non-Small-Cell Lung Carcinoma Patients Treated with Chemotherapy or Immune Checkpoint Inhibitors: An Unexpected Scenario

A. Pani, O. Garrone, M. Scartozzi, 2022, Vaccines.

Case Report: ALK Traslocated Pulmonary Sarcomatoid Carcinoma

P. Marchetti, E. Cortesi, A. Gelibter, 2020 .

Systemic effect of radiotherapy before or after nivolumab in lung cancer: an observational, retrospective, multicenter study

A. Ceribelli, P. Marchetti, R. Chiari, 2021, Tumori.

PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

W. Gianni, G. Carpino, E. Gaudio, 2017, Oncoimmunology.

Use of nivolumab in elderly patients with advanced squamous non-small-cell lung cancer: results from the Italian cohort of an expanded access programme.

F. Cappuzzo, L. Livi, F. de Marinis, 2018, European journal of cancer.

Coexistence of three EGFR mutations in an NSCLC patient: A brief report

G. Giannini, C. Nicolazzo, A. Gradilone, 2018, The International journal of biological markers.

Catheter-associated thrombosis: thromboprophylaxis for cancer patients who carry factor V Leiden?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact of Sarcopenia and Inflammation on Patients with Advanced Non-Small Cell Lung Cancer (NCSCL) Treated with Immune Checkpoint Inhibitors (ICIs): A Prospective Study

P. Marchetti, E. Cortesi, A. Isidori, 2021, Cancers.

A multicenter REtrospective observational study of first-line treatment with PERtuzumab, trastuzumab and taxanes for advanced HER2 positive breast cancer patients. RePer Study

S. Barni, G. Ciliberto, L. Mariani, 2018, Cancer biology & therapy.

Severe rhabdomyolysis associated with pemetrexed-based chemotherapy.

A. Ceribelli, M. Milella, F. Cognetti, 2006, The Lancet. Oncology.

Response to immunotherapy in KRAS G12C mutated NSCLC: a single-centre retrospective observational study

E. Cortesi, C. Nicolazzo, P. Gazzaniga, 2022, Oncotarget.

The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy

P. Ascierto, L. Strigari, P. Marchetti, 2020, Vaccines.

Status of correlation between BMI and response to immunocheck-point inhibitor in advanced non-small-cell lung cancer

P. Marchetti, A. Cortellini, E. Cortesi, 2020, Lung cancer management.

Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease

R. Berardi, G. Mountzios, A. Gelibter, 2022, Drugs in context.

Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer.

L. Filippi, G. Masi, E. Cortesi, 2020, Clinical colorectal cancer.

Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.

M. Pino, M. Milella, F. Cognetti, 2010, The oncologist.

Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer

G. Giannini, E. Cortesi, C. Nicolazzo, 2019, Cancers.

Are dose-finding studies still necessary when targeted therapy is associated with chemotherapy?

R. Labianca, F. Cognetti, F. Loupakis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC)

F. Costanzo, A. Gabriele, F. Cognetti, 2004 .

A feasibility study of gefitinib in association with capecitabine (CAP) and oxaliplatin (OXA) as first-line treatment in patients with advanced colorectal cancer (ACRC).

F. di Costanzo, A. Gabriele, F. Cognetti, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular stool testing for the early detection of colorectal cancer: swan song for p53?

F. Cognetti, A. Fabi, P. Carlini, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Gemcitabine-based polychemotherapy for advanced pancreatic cancer (APC): Is it ready for prime time? A pooled analysis of 3,682 patients (pts) enrolled in 12 phase III trials.

A. Ceribelli, M. Pino, M. Milella, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease

A. Gelibter, G. Metro, D. Marinelli, 2022, Drugs in context.

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

D. Mallardo, P. Ascierto, P. Marchetti, 2019, Journal of Translational Medicine.

Low-molecular-weight heparin versus oral anticoagulant therapy for the long-term treatment of symptomatic venous thromboembolism: Is there any difference in cancer-related mortality?

M. Mandalà, F. Cognetti, A. Fabi, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory Pilot Study of Circulating Biomarkers in Metastatic Renal Cell Carcinoma

P. Marchetti, F. Calabrò, G. Schinzari, 2020, Cancers.

Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy

M. Filetti, L. Landi, G. Minuti, 2021, Journal for ImmunoTherapy of Cancer.

Thyroid disorders in programmed death 1 inhibitor‐treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?

A. Lenzi, P. Marchetti, A. Isidori, 2019, Clinical endocrinology.

A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases

A. Addeo, G. Banna, A. Cortellini, 2021 .

Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.

M. Filetti, L. Landi, G. Minuti, 2021, European journal of cancer.

Circulating CD137 þ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer

Amati, L. Strigari, P. Marchetti, 2022 .

Burned-Out Testicular Cancer: Really a Different History?

M. Bezzi, E. Cortesi, A. Gelibter, 2017, Case Reports in Oncology.

The role of opioids in cancer response to immunotherapy

P. Marchetti, E. Cortesi, A. Botticelli, 2021, Journal of translational medicine.

KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.

M. Filetti, G. Ciliberto, A. Vecchione, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: the multicenter FAMI-L1 study

N. Tinari, M. Filetti, D. Mallardo, 2020, Oncoimmunology.

Italian Nivolumab Expanded Access Program in Nonsquamous Non–Small Cell Lung Cancer Patients: Results in Never‐Smokers and EGFR‐Mutant Patients

E. Vasile, G. Fasola, D. Galetta, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

A. Ceribelli, G. Tortora, M. Milella, 2013, Expert opinion on drug discovery.

TK Inhibitor Pazopanib Primes DCs by Downregulation of the β-Catenin Pathway

P. Marchetti, F. Calabrò, I. Ruscito, 2018, Cancer Immunology Research.

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

E. Vasile, S. Barni, V. Adamo, 2020, Advances in Therapy.

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis.

G. Scagliotti, A. Ceribelli, M. Milella, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Emerging pathways and future targets for the molecular therapy of pancreatic cancer

G. Tortora, M. Pino, D. Melisi, 2011, Expert opinion on therapeutic targets.

Adjuvant chemotherapy in resected colon cancer: When, how and how long?

E. Cortesi, A. Gelibter, A. Emiliani, 2019, Surgical oncology.

The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer

M. Filetti, L. Landi, G. Minuti, 2021, ESMO open.

Efficacy of immunotherapy in lung cancer with co-occurring mutations in NOTCH and homologous repair genes

M. Filetti, G. Ciliberto, A. Vecchione, 2020, Journal for ImmunoTherapy of Cancer.

Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.

A. Marchetti, F. Buttitta, S. Iacobelli, 2009, Neoplasia.

Clinical outcomes of NSCLC patients experiencing early immune-related adverse events to PD-1/PD-L1 checkpoint inhibitors leading to treatment discontinuation

M. Filetti, V. Adamo, M. Tiseo, 2021, Cancer Immunology, Immunotherapy.

Intensified Total Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer: A Phase II Trial.

V. Tombolini, E. Cortesi, F. Iafrate, 2021, Clinical oncology (Royal College of Radiologists (Great Britain)).

Metastatic Renal Cell Carcinoma Management: From Molecular Mechanism to Clinical Practice

P. Marchetti, A. Laghi, C. Ciccarese, 2021, Frontiers in Oncology.

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.

M. Filetti, D. Mallardo, P. Ascierto, 2020, European journal of cancer.

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice

M. Filetti, D. Mallardo, P. Ascierto, 2020, Journal for ImmunoTherapy of Cancer.

Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation

M. Filetti, L. Landi, J. Aerts, 2020, Journal for ImmunoTherapy of Cancer.

M. Filetti, L. Landi, F. Cappuzzo, 2020, Clinical lung cancer.

Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%

M. Filetti, L. Landi, F. Cappuzzo, 2020, Cancer Immunology, Immunotherapy.

Clinicopathologic correlates of pembrolizumab efficacy in patients with advanced NSCLC and a PD-L1 expression of >= 50%.

M. Filetti, L. Landi, F. Cappuzzo, 2020, medRxiv.

Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events.

M. Filetti, D. Mallardo, P. Ascierto, 2020, European journal of cancer.

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors

C. Porta, R. Montironi, Liang Cheng, 2019, Cancers.

Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.

A. Rossi, D. Galetta, S. Novello, 2019, Lung cancer.

Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer

L. Landi, G. Minuti, F. Cappuzzo, 2019, Journal of Immunotherapy for Cancer.

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

N. Tinari, M. Filetti, P. Ascierto, 2019, Journal of Immunotherapy for Cancer.

First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer.

M. Milella, F. Cognetti, L. Moscetti, 2013, World journal of gastroenterology.

Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers

M. Pino, M. Milella, F. Cognetti, 2009, Oncology.

PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients.

A. Vecchione, A. Ceribelli, M. Milella, 2004, Anticancer research.

Docetaxel in Advanced Gastric Cancer Review of the Main Clinical Trials

S. Di Cosimo, A. Alimonti, F. Cognetti, 2003, Acta oncologica.

Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab

E. Vasile, S. Barni, V. Adamo, 2020, Expert opinion on biological therapy.

Comparison of Two Blood-Based Genotyping Tests to Investigate the KRAS G12C Mutation in Patients with Non-Small-Cell Lung Cancer at Failure of First-Line Treatments

G. Giannini, I. Bottillo, P. Grammatico, 2021, Diagnostics.

[Immunotherapy in non-small cell lung cancer patients: back to the future.]

P. Marchetti, F. Cognetti, D. Santini, 2019, Recenti progressi in medicina.

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.

A. Nagler, L. Trakhtenbrot, N. Amariglio, 2004, Experimental Hematology.

Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study

F. Cognetti, L. Moscetti, P. Carlini, 2005, Cancer Chemotherapy and Pharmacology.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti‐HER2 agents in the real world setting

S. Barni, N. Tinari, G. Ciliberto, 2019, International journal of cancer.

Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy.

M. Filetti, L. Landi, G. Minuti, 2021, European journal of cancer.

Comparison of CEA, MCA, CA 15-3 and CA 27-29 in follow-up and monitoring therapeutic response in breast cancer patients.

A. Vecchione, E. Bria, A Vecchione, 1999, Anticancer research.

Evaluation of Drug—Drug Interactions in EGFR-Mutated Non-Small-Cell Lung Cancer Patients during Treatment with Tyrosine-Kinase Inhibitors

R. Preissner, P. Marchetti, G. Galli, 2021, Journal of personalized medicine.

1320PUse of nivolumab in elderly patients with advanced non-squamous NSCLC: Results from the Italian expanded access program (EAP)

E. Vasile, S. Cascinu, F. Verderame, 2017 .

Combination Therapy in Renal Cell Carcinoma: the Best Choice for Every Patient?

M. Bersanelli, N. Borsellino, E. Rossi, 2021, Current Oncology Reports.

Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation

M. Mottolese, M. Milella, F. Cognetti, 2008, Cancer Chemotherapy and Pharmacology.

Incidence of chemotherapy-induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer.

S. Cosimo, M. Mandalà, S. Di Cosimo, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort

M. Filetti, D. Mallardo, P. Ascierto, 2021, Journal of translational medicine.

High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status

M. Filetti, V. Adamo, J. Aerts, 2022, Journal of Hematology & Oncology.

Pilot study of celecoxib and infusional 5‐fluorouracil as second‐line treatment for advanced pancreatic carcinoma

S. Cosimo, M. Milella, F. Cognetti, 2004, Cancer.

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

S. Novello, A. Del Conte, R. Chiari, 2019, In Vivo.

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

E. Cortesi, V. Magri, A. Gelibter, 2017, Oncology.

Sequential chemotherapy in nonsmall‐cell lung cancer

M. Caterino, A. Ceribelli, M. Pino, 2007, Cancer.

Host immune‐inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD‐L1 ≥50% metastatic non‐small cell lung cancer and poor performance status receiving first‐line immunotherapy

F. Cappuzzo, J. Aerts, F. Mazzoni, 2021, Thoracic cancer.

Corrigendum to ‘The lung immuno-oncology prognostic score (LIPS-3): a prognostic classification of patients receiving first-line pembrolizumab for PD-L1 ≥ 50% advanced non-small-cell lung cancer’

M. Filetti, L. Landi, G. Minuti, 2021, ESMO open.

Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

M. Filetti, L. Landi, G. Minuti, 2021, Thoracic cancer.

Old age: biologic versus chronologic.

M. Milella, F. Cognetti, C. Nuzzo, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Celecoxib combined with fixed dose-rate gemcitabine (FDR-Gem)/CDDP as induction chemotherapy for stage III non-small cell lung cancer (NSCLC)

A. Ceribelli, M. Milella, F. Cognetti, 2005 .

Early fatigue in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors: an insight from clinical practice

D. Mallardo, P. Ascierto, P. Marchetti, 2019, Journal of Translational Medicine.

Molecular and genetic bases of pancreatic cancer.

M. Pino, M. Milella, F. Cognetti, 2012, Current Drug Targets.

Gemcitabine‐based combinations for inoperable pancreatic cancer: Have we made real progress?

M. Pino, M. Milella, F. Cognetti, 2007, Cancer.

FEB study: Efficacy treatment evaluation in metastatic colorectal cancer (mCRC) patients (pts) changing monoclonal antibody (MA) after progression with chemotherapy.

I. Sperduti, F. Narducci, G. Cianci, 2010 .

Circulating Natural Killer Cells as Prognostic Value for Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: Correlation with Sarcopenia

E. Cortesi, F. Sciarra, A. Isidori, 2023, Cancers.

Circulating CD137+ T Cells Correlate with Improved Response to Anti-PD1 Immunotherapy in Patients with Cancer

L. Strigari, P. Marchetti, G. Schinzari, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Evaluation of Efficacy of ALK Inhibitors According to Body Mass Index in ALK Rearranged NSCLC Patients—A Retrospective Observational Study

D. Santini, E. Cortesi, I. Sperduti, 2023, Cancers.

Safety and efficacy of combining afatinib and whole-brain radiation therapy in treating brain metastases from EGFR-mutated NSCLC: a case report and literature review

V. Tombolini, E. Cortesi, A. Gelibter, 2022, BJR case reports.

Impact of gefitinib (‘Iressa’) treatment on the quality of life of patients with advanced non-small-cell lung cancer

A. Ceribelli, M. Milella, F. Cognetti, 2005, Journal of Cancer Research and Clinical Oncology.

Fixed dose‐rate gemcitabine infusion as first‐line treatment for advanced‐stage carcinoma of the pancreas and biliary tree

S. Di Cosimo, M. Milella, F. Cognetti, 2005, Cancer.

Non-small cell lung cancer: early stages.

U. Pastorino, A. Ceribelli, F. Cognetti, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Malignant bronchial Abrikossoff's tumor and small cell lung cancer: a case report and review.

A. Vecchione, G. Larosa, E. Bria, 2001, Anticancer research.

Fixed dose-rate gemcitabine infusion as first-line treatment for advanced-stage carcinoma of the pancreas and biliary tree: series of 106 consecutive patients.

M. Milella, F. Cognetti, I. Sperduti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Advances towards the design and development of personalized non-small-cell lung cancer drug therapy

A. Ceribelli, G. Tortora, M. Milella, 2013, Expert opinion on drug discovery.

COX-2 targeting in cancer: a new beginning?

M. Milella, F. Cognetti, A. Fabi, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Type 2 diabetes mellitus and efficacy outcomes from imune checkpoint blockade in patients with cancer.

M. Filetti, D. Mallardo, P. Ascierto, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acute toxic gastric mucosal

I. Medizin, A. Gelibter, A. Gasbarrini, 2005 .

The role of opioids in cancer response to immunotherapy

P. Marchetti, E. Cortesi, A. Botticelli, 2021, Journal of Translational Medicine.

Rheumatic Diseases Development in Patients Treated by Anti-PD1 Immune Checkpoint Inhibitors: A Single-Centre Descriptive Study

F. Conti, A. Botticelli, F. Ceccarelli, 2023, Life.

Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab

E. Cortesi, V. Magri, A. Gelibter, 2017, Oncology.